Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients.

NCT02941549 is registered in ClinicalTrials.gov with Afimmune as lead sponsor.

NCT NCT02941549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02941549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients.
Lead sponsor
Afimmune
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2016
Completion date
March 4, 2019
Enrollment
96 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

non alcoholic fatty liver disease